BWX Technologies (BWXT) Q2 FY26 earnings call: guidance and Q&A

Can you elaborate on the medical business sale, including the considerations for reaching the $800 million valuation and the drivers of the potential range?

Rex explained the unsolicited offer and strategic rationale to focus on core nuclear businesses, noting medical was 3% of sales but required outsized attention. Mike detailed the deal structure: $750 million upfront plus shared economics up to $800 million, covering legacy medical and part of Kinectrics' stable isotope business. He confirmed the offer was compelling and the $800 million target is achievable.

“So a few points. First, that asset wasn't for sale. We certainly weren't going through strategic considerations there. We were approached by the buyer, and they came forward with a very compelling offer financially, but I think an even more compelling strategic growth story for that asset.”

asked by Bob Labick · answered by Rex Geveden

With the PCG acquisition closed, what is the timing and process for updating its incremental capacity for U.S. nuclear work and growth?

Rex stated that the integration and capacity update for PCG will unfold over the next few quarters, likely within a year. This involves assessing BWXT's portfolio and determining the necessary capital investments to optimize PCG's capabilities for U.S. nuclear growth.

“Yes, Bob, I would say that will be something that will unfold over the next few quarters. We've got to assess our portfolio and see what we're going to tuck in over there at PCG and also see what the capital needs are, but it's certainly something that we're working on in earnest right now, but will unfold over the next, let's call it, year.”

asked by Bob Labick · answered by Rex Geveden

You mentioned expecting at least one new nuclear equipment order by year-end. Is this expected to be a gigawatt-class order or more related to SMRs?

Rex clarified that the expected order could come from various opportunities, including SMRs at the Darlington site, AP1000 projects, and X300 opportunities in the U.S. He noted strong momentum and active quoting with GE Vernova and Westinghouse, indicating a broad range of potential sources for the order.

“I think it's certainly among those opportunities, Scott. We've got -- I mean, we certainly expect to get a second half order among the opportunities for the 3 SMRs, additional SMRs at the Darlington site, the AP1000 opportunities and then the X300 opportunities that are in the U.S., there's a lot of momentum around those.”

asked by Scott Deuschle · answered by Rex Geveden

Have you determined the use for the sale receipts from the medical business?

Mike explained that the sale allows BWXT to focus on national nuclear security and commercial nuclear opportunities. Capital allocation priorities include growth investments (CapEx 6-7% of sales), a robust M&A pipeline for strategic fits, potential bond paydowns in the coming years to maintain balance sheet strength, and future share repurchases (none planned for 2026).

“So not exactly. I would say, part of our focus on capital allocation priorities, this was a big part of it because what the sale the medical does is it really allows us to focus on national nuclear security and commercial nuclear opportunities within the portfolio.”

asked by Jeffrey Campbell · answered by Michael Fitzgerald

Could you provide more details on the mPower licensing to Applied Atomics, specifically regarding the 195-megawatt rating and any recent design work?

Rex provided background on mPower, developed from 2008-2014 and shelved due to market conditions after $400 million spent. He confirmed the 195-megawatt rating and stated no incremental design work has been done since 2014. The agreement with Applied Atomics grants them exclusivity for terrestrial applications, with BWXT retaining manufacturing rights and IP, supporting their design and licensing efforts.

“It is rated to 195 megawatts, by the way. We have not done incremental work on that technology since that time. But there has been some interest in it because it was a very elegant design and probably would be attractive in the modern market.”

asked by Jeffrey Campbell · answered by Rex Geveden

How are you thinking about longer-term margins in the Government business, especially with some dilutive programs ramping up, and could they grow into 2027?

Mike noted that initial FY26 guidance of 19% was due to lower-margin new programs (HPDU, DUECE) and older pricing. The updated guidance of 20.5% reflects strong operational performance, efficiency gains, and cost underruns on new programs. He expects continued efforts to drive efficiency and operational performance, with some margin enhancements expected in 2027, but did not provide specific 2027 guidance.

“As we look to '27, I'm not setting '27 guidance at this point. I think we'll give better perspective on that later in the year. I mean the one thing I would just say is, we will have to continue to maintain this performance and some of the performance that we've discussed that we were expecting to see in '27 is starting to show up in '26.”

asked by Matthew Akers · answered by Michael Fitzgerald

What demand signals are needed for BWXT to make a full capital commitment on TRISO fuel production, and what would be the CapEx and timeline?

Rex stated that a 'very, very solid' pipeline of orders is needed. The estimated CapEx for standing up the facility and equipment is a few hundred million dollars, up to $500 million, which would be shared with partner Kairos and offset by a grant from the Wyoming Energy Authority. Mike added that the Project Janus decision, expected this year, is a key milestone for solidifying orders.

“I'd say we'd like to see a pipeline of orders that looks very, very solid. Now we're pretty far down that road. We've got a partner in Kairos. We have $100 million grant from the Wyoming Energy Authority. And so we just need to see that pipeline of opportunities firm up a little bit.”

asked by Mark Shooter · answered by Rex Geveden

What are the gating factors for the upcoming decision on expanding commercial capacity, whether through Mount Vernon, greenfield, or M&A?

Rex indicated that there are no significant stalling factors, as the commercial demand is clear and the need for domestic large component manufacturing with deepwater access is established. The primary remaining factor is sorting out state incentives among New Jersey, Indiana, and one other option for site selection. Plant design and equipment procurements are already proceeding.

“So all we're going through right now is sorting out state incentives amongst New Jersey, Indiana and one other option that we're considering. By the way, we're proceeding with the plant design full out, and we'll proceed with equipment procurements in a short order. So there's nothing that's stalling us out. It's just a matter of site selection at this point, and we'll get to that decision in pretty short order.”

asked by Andre Madrid · answered by Rex Geveden